Veracyte, Inc. Q3 2025 Earnings Recap

VCYT Q3 2025 November 5, 2025

Get alerts when VCYT reports next quarter

Veracyte delivered robust financial performance in Q3 2025, achieving 14% revenue growth year-over-year and a record adjusted EBITDA margin of 30%. The company's strategic focus on core testing products continues to drive impressive volume growth.

Earnings Per Share Beat

$0.51 vs $0.32 est.

+59.4% surprise

Revenue Miss

131872000 vs 135786330 est.

-2.9% surprise

Market Reaction

1-Day +27.46%

5-Day +17.25%

30-Day +31.06%

See VCYT alongside your other holdings

Add to your portfolio — free

Key Takeaways

Total revenue reached approximately $132 million, bolstered by 26% growth in Decipher and 13% growth in Afirma tests.
Adjusted EBITDA margin improved by 650 basis points year-over-year, surpassing the previously set goal of 25%.
Decipher's testing volume exceeded 26,700, marking the 14th consecutive quarter of over 25% year-over-year growth and demonstrating increased clinical utility for advanced disease management.
Strong research backing with 240 publications on Decipher, continuing to establish its relevance in prostate cancer treatment and diagnostics.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit VCYT on AllInvestView.

Next Q1 2026